key: cord-0729491-1r5av5xu
authors: Qayed, Emad; Deshpande, Amar R.; Elmunzer, B. Joseph
title: Low incidence of severe gastrointestinal complications in COVID-19 patients admitted to the intensive care unit: a large, multi-center study
date: 2020-11-12
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.11.009
sha: 9449e2915e653ae0b7e6f413a8f12fbd5ea398af
doc_id: 729491
cord_uid: 1r5av5xu

nan

Patients hospitalized with Coronavirus disease 2019 (COVID-19) often have gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain. 1 However, the rate of gastrointestinal complications in patients with COVID-19 is less well described. Recent reports from a single center have suggested an alarmingly high rate of serious gastrointestinal complications in critically ill patients with COVID-19. 2, 3 In a retrospective review of 92 patients with severe COVID-19 admitted to the intensive care unit (ICU), 44 patients (48%) had ileus, 4 (4%) had intestinal ischemia, and 2 (2%) had Ogilvie syndrome. 2 Several other case reports have described intestinal ischemia in the setting of COVID-19. 4 However, reports from single centers should be interpreted with caution due to small sample sizes and limited generalizability to patients from wider geographic distributions. The aim of this study was to assess the rate of serious gastrointestinal complications in COVID-19 patients admitted to the ICU in a large, geographically diverse sample.

This study analyzed data from a cohort of COVID-19 patients who were hospitalized at 36 medical centers in the United States and Canada. The institutional review board at each participating center approved the study.

The first 50-100 consecutive adult (age ≥18 years) patients with a confirmed diagnosis of COVID-19 were enrolled from each center. For each patient, all available relevant clinical data (symptoms, laboratory and imaging results, clinical notes, and endoscopic findings) were collected by review of electronic health records. Demographic and hospitalization characteristics, J o u r n a l P r e -p r o o f including length of hospital stay, ICU stay, and discharge disposition were also recorded. Data were collected between April 15 and June 5, 2020, and entered into a secure electronic database.

The primary outcome of this study was the rate of any severe gastrointestinal complication. The hepatic complication of interest was severe liver enzyme elevation (alanine aminotransferase (ALT) elevation >1000 unit/L). Gastrointestinal complications included any significant luminal and pancreaticobiliary medical or surgical disorder such as acute pancreatitis, acute cholecystitis, acute mesenteric ischemia, intestinal obstruction, gastrointestinal infections (e.g. Clostridioides difficile), and gastrointestinal bleeding requiring endoscopic evaluation or intervention.

Data were analyzed using descriptive statistics, with categorical variables summarized using proportions and continuous variables summarized using means with standard deviation (SD) or medians with interquartile range (IQR). All data analyses were conducted using SAS 9.4 (SAS Institute, Inc. Cary, North Carolina). 

In this study, we found an overall low rate (5.1%) of severe gastrointestinal complications in COVID-19 patients admitted to the ICU. The majority of these complications were related to severe liver enzyme elevation (48.9%, or 2.5% of overall population), followed by gastrointestinal bleeding (22.2%, or 1.1% of all patients) and Clostridioides difficile infection (13.3%, or 0.7% of all patients). The rate of other luminal and pancreaticobiliary complications was very low.

In particular, the rate of intestinal ischemia -previously reported to be in excess of 4% 2 -was only 0.2% in this cohort. It is increasingly apparent that COVID-19 represents a hypercoagulable disorder that is associated with a higher incidence of venous thromboembolism. Additionally, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been found to infect the endothelial cells of different vascular beds in the heart, small bowel, and lungs. 5 Therefore, it is postulated that endotheliitis caused by COVID-19 leads to microthrombus formation and organ J o u r n a l P r e -p r o o f ischemia. However, consistent with our findings, a recent study of 3089 patients with COVID-19 infection at two hospitals in Spain found that only 12 patients (0.4%) required surgical consultation, of which 4 patients (0.13%) developed bowel ischemia and perforation. 6 Similarly, a multicenter prospective cohort study from France that evaluated the rate of thrombotic complications in 150 COVID-19 patients admitted to the ICU found that although sixty-four patients (42.7%) developed clinically relevant thrombotic complications, only 1 (0.7%) developed mesenteric ischemia. 7 In conclusion, in this multicenter study involving a large number of ICU patients with COVID-19 across North America, we found a low incidence of severe gastrointestinal complications, consistent with rates reported in critically ill patients in general. 8 Despite recent reports of increased risk of intestinal ischemia in COVID-19 patients, our study found a low rate of this complication and therefore provides reassurance that this phenomenon may not be as problematic as initially believed.

J o u r n a l P r e -p r o o f

Division of Digestive Health and Liver Diseases

J o u r n a l P r e -p r o o f